Using clozapine to reduce violence in people with schizophrenia
7/7 Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
This study is looking at whether clozapine, a medication for schizophrenia, can help reduce violent behavior in people who are at high risk, and it involves 280 participants receiving either clozapine or standard care over six months to see how it affects their behavior.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Augusta University NIH-funded |
| Lab location | 1 site (Augusta, United States) |
| Project ID | NIH-10876448 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of clozapine, an antipsychotic medication, in reducing the risk of violent behavior among individuals with schizophrenia. The study will involve a randomized clinical trial with 280 participants who are at high risk for violence, comparing clozapine treatment to standard care over a 24-week period. The trial aims to provide robust evidence on how clozapine can help mitigate aggression and improve outcomes for patients in community settings. Participants will be monitored for violent acts and other related behaviors throughout the study.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with schizophrenia who are identified as being at high risk for violent behavior.
Not a fit: Patients with schizophrenia who are not at risk for violence or those who do not meet the study's inclusion criteria may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for individuals with schizophrenia, potentially reducing violence and enhancing their quality of life.
How similar studies have performed: Previous studies have suggested that clozapine may be more effective than other antipsychotics in reducing aggression, but this trial aims to provide more definitive evidence in a community setting.
Where this research is happening
Augusta, United States
- Augusta University — Augusta, United States (Active)
Researchers
- Principal investigator: Mcevoy, Joseph Patrick — Augusta University
- Study coordinator: Mcevoy, Joseph Patrick
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.